Literature DB >> 22007836

Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection.

J W Jang1, S H Yoo, J H Kwon, C R You, S Lee, J H Lee, K W Chung.   

Abstract

BACKGROUND  The production of hepatitis B surface antigen (HBsAg) may evolve during long-lasting virus-host interactions in chronic hepatitis B (CHB). The impact of age on HBsAg production remains unclear. AIM  To determine the age-specific distribution patterns of HBsAg and related factors during the natural course of CHB infection. METHODS  Seven hundred and sixty-eight untreated HBsAg carriers were enrolled in the study. The parameters and distribution patterns of HBsAg were evaluated in relation to age and immune phases. RESULTS  The HBsAg levels were significantly lower in the HBeAg-negative stage, with the lowest levels in inactive carriers. The HBsAg tended to decrease from hepatitis to cirrhosis and to hepatocellular carcinoma, and from Child-Pugh class A to B and to C. Age and HBV DNA were independently associated with HBsAg levels. In HBeAg-positive patients, the HBsAg levels were distributed in a triphasic-like decline pattern by 2 logs across age strata. For HBeAg-negative patients, the titres in inactive carriers exhibited a 2-log reduction, but remained unchanged over age strata in patients with HBeAg-negative hepatitis. The ratios of HBsAg/HBV-DNA were highest, but steadily decreased with age in inactive carriers, whereas the levels remained largely unchanged over the entire age strata in patients with HBeAg-negative hepatitis. CONCLUSIONS  Age and HBV DNA levels are independent parameters of HBsAg levels. During the natural course of CHB infection, HBsAg levels decrease with age and disease progression, but the patterns are significantly different between the immune phases of CHB. This information may contribute to our understanding of the immunopathogenesis of chronic hepatitis B and management involving HBsAg quantification.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007836     DOI: 10.1111/j.1365-2036.2011.04888.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.

Authors:  Gong-Ying Chen; Meng-Fei Zhu; Da-Liang Zheng; Yan-Ting Bao; Jie Wang; Xiang Zhou; Guo-Qiang Lou
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

2.  Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.

Authors:  Hae Lim Lee; Jeong Won Jang; Ji Won Han; Sung Won Lee; Si Hyun Bae; Jong Young Choi; Nam Ik Han; Seung Kew Yoon; Hee-Je Kim; Seok Lee; Seok-Goo Cho; Chang-Ki Min; Dong-Wook Kim; Jong Wook Lee
Journal:  Dig Dis Sci       Date:  2019-04-13       Impact factor: 3.199

3.  Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics.

Authors:  Chung-Feng Huang; Ming-Lun Yeh; Jia-Jung Lee; Mei-Chin Chen; Chia-Yen Dai; Jee-Fu Huang; Jer-Ming Chang; Hung-Chun Chen; Shang-Jyh Hwang; Wan-Long Chuang; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2014-03-19       Impact factor: 6.047

4.  The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status.

Authors:  Mo-Han Liu; Qin-Yan Chen; Tim J Harrison; Guo-Jian Li; Hai Li; Xue-Yan Wang; Yu Ju; Jin-Ye Yang; Zhong-Liao Fang
Journal:  J Med Virol       Date:  2015-04-16       Impact factor: 2.327

5.  Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection.

Authors:  Lu Zhang; Ming-Hui Li; Wei-Hua Cao; Tian-Lin Qi; Yao Lu; Shu-Ling Wu; Hong-Xiao Hao; Ge Shen; Ru-Yu Liu; Lei-Ping Hu; Min Chang; Wen-Hao Hua; Shu-Jing Song; Gang Wan; Yao Xie
Journal:  Chin Med J (Engl)       Date:  2017-11-20       Impact factor: 2.628

6.  Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection.

Authors:  Yayun Liu; Meng Jiang; Jianya Xue; Hongli Yan; Xuesong Liang
Journal:  BMC Gastroenterol       Date:  2019-04-16       Impact factor: 3.067

7.  Model to predict on-treatment restoration of functional HBV-specific CD8+ cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B.

Authors:  Julia Peña-Asensio; Henar Calvo; Joaquín Miquel; Eduardo Sanz-de-Villalobos; Alejandro González-Praetorius; Miguel Torralba; Juan-Ramón Larrubia
Journal:  Aliment Pharmacol Ther       Date:  2022-02-27       Impact factor: 9.524

8.  The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis.

Authors:  Jung Hyun Kwon; Jeong Won Jang; Young Woon Kim; Sung Won Lee; Soon Woo Nam; Dongwook Jaegal; Seungok Lee; Si Hyun Bae
Journal:  BMC Gastroenterol       Date:  2015-10-23       Impact factor: 3.067

9.  Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection.

Authors:  Simon B Larsson; Sebastian Malmström; Charles Hannoun; Gunnar Norkrans; Magnus Lindh
Journal:  Virol J       Date:  2015-12-09       Impact factor: 4.099

10.  Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.

Authors:  Teresa Broquetas; Montserrat Garcia-Retortillo; Juan José Hernandez; Marc Puigvehí; Nuria Cañete; Susana Coll; Beatriz Cabrero; Maria Dolors Giménez; Ricard Solà; José A Carrión
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.